Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- PMDA’s Preventative Measures for Document Losses Focus on Traceability, Digitalizing
March 27, 2019
- Japan’s Direct Patient ADR Reporting System Now in Full Operation
March 27, 2019
- Nesp Biosame Likely to Be Priced at 70% of Originator as Stopgap Measure
March 26, 2019
- JMA Reps Oppose Reclassification of Epadel OTC despite No Serious ADR Reports: MHLW Safety Panel
March 26, 2019
- Patient ADR Reporting System to Go into Full-Scale Operation by March-End
March 26, 2019
- PMDA Chief Kondo to Step Down after 11 Years in Charge
March 25, 2019
- “Drugs for Specific Use” under Amended PMD Law Covers Pediatric Use, Antimicrobial Resistance: Official
March 22, 2019
- LDP Lawmakers Not So Positive about Reflecting Societal Values to Drug Prices; They Don’t Know How
March 22, 2019
- MHLW Orders Label Revisions for Takecab, Clozapine and More
March 20, 2019
- Japan Cabinet OKs Bill to Amend PMD Law
March 20, 2019
- Generic Drug Use Rates Particularly Low for Insurance Societies of Research-Driven Drug Makers: MHLW
March 20, 2019
- MHLW Council Rejects OTC Switches of 4 Alzheimer’s Drugs
March 19, 2019
- MHLW Council Recommends OTC Switch of Polycarbophil Calcium
March 19, 2019
- PMD Bill Clears LDP Review, Cabinet OK Slated for March 19
March 18, 2019
- MHLW Council to Draft Negotiation Rules on Supply of Unapproved Drugs under Patient-Initiated Mix Care Scheme
March 18, 2019
- Japan Cabinet OKs PMDA Review Fee Rise from April 1
March 18, 2019
- MHLW Seeks Opposition Party Understanding on Removal of Officer Change Order Provision from Amendment Bill for PMD Law
March 15, 2019
- MHLW Grants Orphan Status to Cx601, Takeda’s 1st Cell Therapy
March 15, 2019
- MHLW to Draw Up Guidelines on Registry Data Use for Submissions: Clinical Innovation Network Initiative
March 15, 2019
- HSC Committee Continues to Discuss Reorganizing Core Clinical Research Hospitals
March 15, 2019
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…